At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
AP-SA02 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy for the Treatment of Adults With Bacteremia Due to Staphylococcus Aureus
In Brief
A Phase 2 clinical trial evaluating AP-SA02 and Placebo for Bacteremia and 4 related conditions. Completed, enrolled 56 participants across 28 sites in 2 countries.
Detailed Summary
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
CountriesAustralia, United States
CollaboratorsUnited States Department of Defense
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartApr 2022
Primary CompletionNov 2024
Study CompletionJan 2025
TodayJul 2026
First PostedJan 11, 2022
Enrollment StartApr 26, 2022
Primary CompletionNov 7, 2024
Study CompletionJan 14, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.5 years ago
Interventions
AP-SA02biological
Bacteriophage administered via intravenous bolus infusion
Placeboother
Inactive Placebo administered via intravenous bolus infusion